| Dr Lal PathLabs | |
| Type: | Public |
| Traded As: | |
| Industry: | Healthcare |
| Predecessors: | --> |
| Successors: | --> |
| Founded: | 1949 |
| Founder: | S. K. Lal |
| Founders: | --> |
| Hq Location City: | Delhi |
| Hq Location Country: | India |
| Num Locations: | 233[1] |
| Areas Served: | --> |
| Key People: | Arvind Lal (Chairman) |
| Brands: | Swasthfit, Sugarnme, OncoPro, NephroPro |
| Revenue: | (FY22) |
| Net Income: | (FY22)[2] |
| Owners: | --> |
| Num Employees: | 3941 (2019) |
| Slogans: | --> |
Dr Lal PathLabs Limited is an Indian service provider of diagnostic and related healthcare tests. Based in New Delhi, the company offers tests on blood, urine and other human body viscera.
Dr Lal PathLabs was started in 1949, by the late S. K. Lal.[3] [4] Lal was a Junior Doctor in the British Indian Army and studied pathology from the Armed Forces Medical College in Pune, with additional training in pathology at Cook County Hospital in Chicago.[5] The main operation of Dr Lal PathLabs deals with the performing of diagnosis and testing, including routine tests (including blood tests), specialized tests (e.g., viral and bacterial infection tests) and preventive screenings.
In 2014, Dr Lal PathLabs acquired the APL Clinical Institute of Clinical Laboratory & Research Private Limited.[6]
Dr Lal PathLabs launched its IPO in 2015.[7] The company got listed on BSE and NSE on 23 December 2015.[8]
In 2021, Dr Lal PathLabs acquired Suburban Diagnostics for an enterprise value of 925 crore in an all-cash deal.[9]
The company has 200 laboratories and diagnostic centres with approximately 5000+ collection centres across India. They have also worked with BD India to open a "Centre of Excellence in Phlebotomy", a centre for training healthcare in the process of safely collecting blood samples.[10]
While Zika has not been reported in India (as of 6 February 2016), on 3 February 2016, Dr Lal PathLabs and other competing pathology labs announced they were preparing Zika test kits.[17] Dr Lal PathLabs reported they plan to sell their kits for Rs 4500 (€60). However, several days later IndiaToday reported: "the Union Ministry of Health pulled up private players, saying they cannot cash in on a public health emergency" and also reported that Dr. Vandana Lal (executive director of Dr Lal PathLabs) stated: "We don't want to talk on this matter. We don't have any tests for Zika virus and we are also not importing any test kits for the same. If at all we plan to do something, we will take the government's prior permission."[18]
According to an October 2020 report, for months, the company stored hundreds of massive spreadsheets containing sensitive patient data in an Amazon Web Services storage bucket without a password. TechCrunch was the first news source to report the data breach.[19] [20]